BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27842505)

  • 1. The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma.
    Sato Y; Fujimoto D; Uehara K; Shimizu R; Ito J; Kogo M; Teraoka S; Kato R; Nagata K; Nakagawa A; Otsuka K; Hamakawa H; Takahashi Y; Imai Y; Tomii K
    BMC Cancer; 2016 Nov; 16(1):890. PubMed ID: 27842505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study.
    Ono A; Takahashi T; Mori K; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Nakajima T; Endo M; Yamamoto N
    BMC Cancer; 2013 Jul; 13():354. PubMed ID: 23879483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung.
    Park SY; Lee JG; Kim J; Park Y; Lee SK; Bae MK; Lee CY; Kim DJ; Chung KY
    Lung Cancer; 2013 Feb; 79(2):156-60. PubMed ID: 23206831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma.
    Washino S; Hirai M; Matsuzaki A; Kobayashi Y
    Urol Int; 2011; 87(4):420-8. PubMed ID: 22041857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma.
    Shirasu H; Ono A; Omae K; Nakashima K; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Takahashi T
    Tumour Biol; 2018 Feb; 40(2):1010428318760420. PubMed ID: 29463190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Takeuchi A; Oguri T; Sone K; Ito K; Kitamura Y; Inoue Y; Asano T; Fukuda S; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Anticancer Res; 2017 Oct; 37(10):5771-5776. PubMed ID: 28982900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
    Chen F; Luo X; Zhang J; Lu Y; Luo R
    Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum tumor markers in patients with lung cancer.
    Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
    Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
    Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
    Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
    Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy.
    Gauthé M; Richard-Molard M; Rigault E; Buecher B; Mariani P; Bellet D; Cacheux W; Lièvre A
    BMC Cancer; 2018 Apr; 18(1):417. PubMed ID: 29653564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
    Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
    Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer.
    Cabrera-Alarcon JL; Carrillo-Vico A; Santotoribio JD; Leon-Justel A; Sanchez-Gil R; Gonzalez-Castro A; Guerrero JM
    Clin Lab; 2011; 57(11-12):1011-4. PubMed ID: 22239035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
    Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
    Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer.
    Gwak HK; Lee JH; Park SG
    Asian Pac J Cancer Prev; 2014; 15(12):4933-8. PubMed ID: 24998567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.